Energy, healthcare triggers Wall Street gains; Nasdaq 100 hits 15-year high

US Stocks went up across sectors Monday largely due to the increases in the energy sector and the growing acquisition activities in healthcare. Reuters reported that the increases on the first trading day of November happened right after the impressive October figure, which is the best monthly performance of the major indexes in the last four years.

Read Full Article

AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal

AbbVie Inc (ABBV.N) is to buy Pharmacyclics Inc (PCYC.O) for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field.

Read Full Article

Big Pharma faces up to new price pressure from aggressive insurers

The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications.

Read Full Article

Galapagos loses partner on inflammatory bowel drug

Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a program to develop a new drug to treat bowel disease.

Read Full Article

AbbVie adds children's AIDS drugs to shared patent pool

U.S. drugmaker AbbVie has added two HIV medicines for children to a shared patent pool in an initiative that should speed the development of cheap new pediatric formulations for use in poor countries.

Read Full Article

Scuttled deals worth $580 billion put hedge funds on back foot

Hedge funds specializing in bets on mergers and acquisitions are starting to see investors withdraw funds, prompting them to take a more cautious approach after being caught out by more than 500 corporate deals globally failing this year.

Read Full Article

Elliott Associates may sue AbbVie over scuttled deal

Hedge fund Elliott Associates may take legal action against pharmaceuticals company AbbVie Inc for scuttling a merger deal with Shire Plc.

Read Full Article

AbbVie says $55 billion acquisition of Shire officially dead

U.S. drugmaker AbbVie Inc (ABBV.N) said on Monday it has reached agreement with Shire Plc (SHP.L) to officially call off its proposed $55 billion purchase of the Irish company, and will pay Shire a $1.64 billion breakup fee for walking away from the deal.

Read Full Article

Shire CFO to leave drugmaker as AbbVie drops bid

British drugmaker Shire (SHP.L) will lose its interim chief financial officer early next year to water supplier Severn Trent (SVT.L), the latest blow for Shire, whose proposed $55-billion acquisition by U.S. rival AbbVie (ABBV.N) was aborted last week.

Read Full Article

AbbVie says to reconsider recommendation for Shire acquisition

AbbVie Inc (ABBV.N) said it intends to reconsider its recommendation to its shareholders to vote in favor of the 32 billion pound ($54.7 billion) merger with Shire Plc (SHP.L) due to the changing U.S. tax regulations.

Read Full Article

Hundreds of firms join global hunt for copycat biotech drugs

Hundreds of companies around the world are chasing an emerging market for cheaper copies of costly biotech drugs, with more than 700 so-called biosimilars now in development or already approved, according to a major study of the sector.

Read Full Article

AstraZeneca, Shire fall as U.S. tax move punctures deal hopes

Shares in drugmakers AstraZeneca (AZN.L) and Shire (SHP.L) both fell more than 5 percent on Tuesday after the U.S. Treasury took steps to curb "inversion" deals that allow companies to escape high U.S. taxes by reincorporating abroad.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics